Payment overview · 2025
General Payments
$836.82
42 reported records · 10 companies
Healthcare provider profile · identity verified
Michael Drew Anthony, MD
Allopathic & Osteopathic Physicians|General Practice · STARKVILLE, MS · NPI 1679641450
Verified facts
What the public records show
CMS Open Payments records show Michael Drew Anthony, MD received $836.82 in general payments during 2025 across 42 reported records.
AstraZeneca Pharmaceuticals LP accounted for 69.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $582.92 | 69.7% | 29 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.80 | 6.2% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $46.63 | 5.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.36 | 5.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.05 | 2.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.94 | 2.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.64 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.11 | 2.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.20 | 1.9% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.17 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $836.82 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $234.56 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $173.52 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $164.23 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51.80 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| VTAMA Normalized: vtama |
Drug | Organon LLC | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 113 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 72 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 703 | 206 |
| Atorvastatin Calcium | Atorvastatin Calcium | 598 | 162 |
| Levothyroxine Sodium | Levothyroxine Sodium | 491 | 125 |
| Metformin Hcl | Metformin Hcl | 436 | 136 |
| Meloxicam | Meloxicam | 422 | 142 |
| Pantoprazole Sodium | Pantoprazole Sodium | 415 | 107 |
| Omeprazole | Omeprazole | 394 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 362 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 355 | 114 |
| Simvastatin | Simvastatin | 333 | 87 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 290 | 92 |
| Gabapentin | Gabapentin | 262 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 254 | 76 |
| Losartan Potassium | Losartan Potassium | 238 | 73 |
| Carvedilol | Carvedilol | 217 | 43 |
| Furosemide | Furosemide | 205 | 58 |
| Sertraline Hcl | Sertraline Hcl | 199 | 36 |
| Lisinopril | Lisinopril | 198 | 57 |
| Valsartan | Valsartan | 190 | 64 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 189 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 176 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 47 |
| Allopurinol | Allopurinol | 170 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 53 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 161 | 46 |
| Potassium Chloride | Potassium Chloride | 150 | 42 |
| Prednisone | Prednisone | 150 | 88 |
| Trazodone Hcl | Trazodone Hcl | 146 | 50 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 131 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 38 |
| Famotidine | Famotidine | 127 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 36 |
| Montelukast Sodium | Montelukast Sodium | 124 | 37 |
| Irbesartan | Irbesartan | 122 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 25 |
| Eliquis | Apixaban | 113 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 108 | 33 |
| Xarelto | Rivaroxaban | 100 | 21 |
| Ozempic | Semaglutide | 97 | 18 |
| Glimepiride | Glimepiride | 95 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 24 |
| Jardiance | Empagliflozin | 82 | 16 |
| Clonazepam | Clonazepam | 81 | 21 |
| Alprazolam | Alprazolam | 80 | 18 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 79 | 19 |
| Cefprozil | Cefprozil | 76 | 65 |
| Atenolol | Atenolol | 75 | 25 |
| Colchicine | Colchicine | 74 | 28 |
| Tradjenta | Linagliptin | 74 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 72 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 11 |
| Amoxicillin | Amoxicillin | 68 | 60 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 13 |
| Metformin Hcl Er | Metformin Hcl | 65 | 21 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 58 | 20 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 57 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 19 |
| Donepezil Hcl | Donepezil Hcl | 55 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 55 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 14 |
| Ezetimibe | Ezetimibe | 52 | 15 |
| Chlorthalidone | Chlorthalidone | 51 | 18 |
| Spironolactone | Spironolactone | 50 | 18 |
| Tramadol Hcl | Tramadol Hcl | 49 | 24 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Lovastatin | Lovastatin | 48 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 13 |
| Celecoxib | Celecoxib | 42 | 15 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 42 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 41 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 18 |
| Clonidine Hcl | Clonidine Hcl | 39 | 12 |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Verapamil Er | Verapamil Hcl | 37 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 16 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Finasteride | Finasteride | 29 | 13 |
| Ketoconazole | Ketoconazole | 29 | 14 |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 22 |
| Lorazepam | Lorazepam | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 11 |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Verapamil Sr | Verapamil Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 12 |
| Estradiol (Once Weekly) | Estradiol | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Naproxen | Naproxen | 15 | 12 |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $836.82 · 42 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BOTOX, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, JARDIANCE, MOUNJARO, NURTEC ODT, OFEV, VTAMA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error